GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Degree of Operating Leverage

EYPT (EyePoint Pharmaceuticals) Degree of Operating Leverage : 6.84 (As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is EyePoint Pharmaceuticals Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. EyePoint Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 6.84. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for EyePoint Pharmaceuticals's Degree of Operating Leverage or its related term are showing as below:

EYPT's Degree of Operating Leverage is ranked worse than
89.55% of 880 companies
in the Biotechnology industry
Industry Median: -0.02 vs EYPT: 6.84

EyePoint Pharmaceuticals Degree of Operating Leverage Historical Data

The historical data trend for EyePoint Pharmaceuticals's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Degree of Operating Leverage Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.36 5.31 7.21 -2.68 -15.77

EyePoint Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -0.35 1.28 -15.77 6.84

Competitive Comparison of EyePoint Pharmaceuticals's Degree of Operating Leverage

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Degree of Operating Leverage falls into.


;
;

EyePoint Pharmaceuticals Degree of Operating Leverage Calculation

EyePoint Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -150.319 (Mar. 2025) / -82.434 (Mar. 2024) - 1 )/( 56.042 (Mar. 2025) / 50.019 (Mar. 2024) - 1 )
=0.8235/0.1204
=6.84***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


EyePoint Pharmaceuticals  (NAS:EYPT) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


EyePoint Pharmaceuticals Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Executives
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Goran Ando director
Wendy F Dicicco director
Nancy Lurker director, officer: President and CEO PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
David R Guyer director ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
David Scott Jones officer: SVP & Chief Commercial Officer C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
Dario A. Paggiarino officer: Chief Medical Officer 4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Ye Liu director ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Michael Craig Pine officer: Chief Corp Dev.&Strat. Officer C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p. 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Anthony P Adamis director 3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension 10 percent owner 56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston officer: Chief Financial Officer 124 CHATHAM STREET, CHATHAM NJ 07928
John B. Landis director 1700 KENT AVENUE, WEST LAFAYETTE IN 46906